CN101244153A - Application of alkekengi in preparing medicament for treating digestive system disease, product and preparation - Google Patents
Application of alkekengi in preparing medicament for treating digestive system disease, product and preparation Download PDFInfo
- Publication number
- CN101244153A CN101244153A CNA200810300310XA CN200810300310A CN101244153A CN 101244153 A CN101244153 A CN 101244153A CN A200810300310X A CNA200810300310X A CN A200810300310XA CN 200810300310 A CN200810300310 A CN 200810300310A CN 101244153 A CN101244153 A CN 101244153A
- Authority
- CN
- China
- Prior art keywords
- seu fructus
- calyx seu
- fructus physalis
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of morelberry in the preparation of medicines for curing digestive system diseases, the product and the preparation method, wherein, the medicine adopts moreberry as material; the moreberry can be superfinely pulverized directly or extracted with water or ethanol to obtain the extraction, so as to prepare into various medicament forms based on traditional preparation technology. The application overcomes the disadvantages of the prior art and provides the application of morelberry in the preparation of medicines for curing digestive system diseases. The medicine has the advantages of simple preparation method, low cost, obvious treatment effect, less adverse reaction, effective treatment of various digestive system diseases and no relapse after recovery.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicine pharmacy, particularly relate to Calyx seu fructus physalis application in the medicine of preparation treatment digestive system disease and products thereof and preparation method.
Background technology
Digestive system disease comprises gastric ulcer, duodenal ulcer, acute or chronic gastritis, atrophic gastritis, enteritis, colitis, esophagitis, cholecystitis, hepatitis (containing viral and non-viral hepatitis), pancreatitis, diabetes, gastric cancer, the esophageal carcinoma, rectal cancer, colon cancer, visceral pains such as gastrointestinal, liver cirrhosis, gastroptosis, dyspepsia, inappetence, diseases such as dysentery, be the commonly encountered diseases that a class comprises multiple disease, its main clinical manifestation has dysphagia, heartburn, anorexia or anorexia, feel sick, vomiting, belch, acid regurgitation, stomachache, abdominal distention, hematemesis, melena, diarrhoea and tenesmus, constipation, jaundice, blood glucose increases etc.
According to " Chinese medicine voluminous dictionary " record, Calyx seu fructus physalis (Physalis alkekengi L.var.franchetii (Mast.) Mak.) is a Solanaceae Physalis perennial herb, is commonly called as under Miss, Calyx Seu Fructus Physalis, Fructus Seu Herba Pubescentis, Calyx Seu Fructus Physalis, Herba seu Fructus Physalis Minimae, the leaf lamp etc.Mainly contain physalin A, physalin B, physalin C, luteolin and luteolin-7-β-D-glycoside in the Calyx seu fructus physalis.Calyx seu fructus physalis sour in the mouth hardship, cold in nature, go into lung, spleen two warps, have the effect of heat clearing away, detoxifcation, diuresis, cure mainly heat syndrome cough, pharyngalgia, jaundice, dysentery, edema, furuncle, diseases such as erysipelas.Its pharmacological action mainly contains (1) antibacterial action Calyx seu fructus physalis decoct has inhibitory action to Song Nei Shi bacillus, and the Calyx seu fructus physalis antibiotic effective ingredient thinks that tentatively at oily liquid, this part has inhibitory action to bacillus pyocyaneus, staphylococcus aureus in vitro.External fungistatic effect of Calyx seu fructus physalis and the clinical dysentery curative effect of controlling are not inconsistent.What (2) effect in excited uterus proposed in one's early years has the hystonin of excitation to the isolated rabbit uterus.Its fruit is according to the cloud effect of hastening parturition.(3) the real and fruit capsule of other effect japanic acid berry has analgesic and cardiotonic, and this effect that the meaning Calyx seu fructus physalis is arranged is with wherein contained oxalic acid is relevant, and act on faint, no using value.Hystonin is injected in animal, and the performance brain suppresses, if with a large amount of, can make respiratory paralysis and dead.External once with the leaf of its congener, really make diuretic.The report that treatment infantile inflammation of upper respiratory tract disease is arranged clinically.
Number of patent application be CN98119025.1 patent disclosure a kind of Calyx seu fructus physalis health promoting wine, it has pharynx-clearing throat-benefiting, reduces the effect of throat irritation, number of patent application is that the patent application of CN200410030860.6 discloses a kind of medicine for the treatment of upper respiratory tract infection, number of patent application is that the patent application of CN200510016677.5 discloses a kind of groundcherry injection, is used for the treatment of diseases such as pharyngitis, antiadoncus, fever.Number of patent application is that the patent application of CN200510016675.6 discloses a kind of Calyx seu fructus physalis intestinal recovery capsule, it is to be prepared from by Calyx Physalis seed and Radix Glycyrrhizae (processed with honey), only be used for the treatment of diseases such as dysentery, enteritis, colitis, it is its medicinal raw material that this patent is just got Calyx Physalis seed, to other parts abandon and need not, caused the waste of resource.Calyx seu fructus physalis intestinal recovery capsule is to be formed by Calyx Physalis seed and Radix Glycyrrhizae (processed with honey) compound recipe, and the toxic and side effects of this compound preparation is clear and definite not enough, and is formed by two kinds of crude drug compound recipes, the corresponding production cost that increased, and product quality is also wayward.
Summary of the invention
Technical problem to be solved by this invention provides Calyx seu fructus physalis application in the medicine of preparation treatment digestive system disease and products thereof and preparation method.Medicine of the present invention is the preparation of Calyx seu fructus physalis or the preparation of its extract, and preparation method is simple, and cost is low, and preparation can effectively be treated various digestive system disease; The present invention is used as medicine with Calyx seu fructus physalis, and wherein curative effect is good with the curative effect of root, stem, leaf, few like this with or without the seed of Calyx seu fructus physalis, Calyx Physalis seed can be used for plantation, can this plant resources of reasonable protection.
In order to solve the problems of the technologies described above, the present invention adopts following technical scheme:
The application of Calyx seu fructus physalis in the medicine of preparation treatment digestive system disease.
The application of Calyx seu fructus physalis in the medicine of preparation treatment digestive tract ulcer.
The application of Calyx seu fructus physalis in preparation treatment dyspepsia, shortage gastric motility, gastritis, gastroptosis, gastric cancer, esophagitis, cholecystitis, pancreatitic medicine.
The application of Calyx seu fructus physalis in the medicine of preparation treatment rectal cancer, colon cancer.
The application of Calyx seu fructus physalis in the medicine of preparation treatment hepatitis, liver cirrhosis, hepatocarcinoma.
A kind of medicine for the treatment of digestive system disease, it is to be that crude drug is prepared from the Calyx seu fructus physalis.Wherein, Calyx seu fructus physalis comprises root, stem, leaf, flower, fruit and the seed of Calyx seu fructus physalis, root, stem, the leaf of medicinal one or more positions, especially Calyx seu fructus physalis wherein, and therapeutic effect is better.
The present invention also provides two kinds of preferred manufacturing procedure of the medicine of above-mentioned treatment digestive system disease:
Method one, with the Calyx seu fructus physalis micronizing, preparation process is made various dosage forms routinely.
Method two, get Calyx seu fructus physalis and add water or ethanol extraction, filter, filtrate is condensed into extractum, and preparation process is made various dosage forms routinely.
Concrete preparation method is: gets Calyx seu fructus physalis and pulverizes, adds 3～20 times of water gagings or ethanol extraction 1～3 time, and filtration, merging filtrate, it is 1.00～1.50 extractum that filtrate is concentrated into 80 ℃ of relative densities, preparation process is made various dosage forms routinely.
Wherein, water or alcoholic acid extracting method comprise that decoction, microwave extraction and percolation extract; The method for concentration of filtrate comprises that vacuum decompression concentrates and microwave vacuum drying.
Technical scheme of the present invention provides the single preparations of ephedrine with the prepared treatment digestive system disease of Calyx seu fructus physalis, also can carry out compatibility and prepare the compound preparation that is used for the treatment of digestive system disease that comprises Calyx seu fructus physalis with Calyx seu fructus physalis and other crude drug.
Contained chemical constituent in the Calyx seu fructus physalis: steroidal class, alkaloids, sterols, lipid, inorganic elements, pigment, amino acids, saccharide and other compositions etc.(1) steroidal class: physalin (Physalin) compounds, physalin isomer, new physalin and different physalin, wityaphysalin.(2) alkaloids: the alkaloid of Calyx seu fructus physalis comprises: 3A tigloidine, tigloidine, tropine, pseudotropine alkali, N-oxidation-3A-tigloidine, Cuscohygrine, 1B-amino-2A, 3B, 5B-trihydroxy cycloheptane, the plain class of DAWANHUA.(3) sterols: all contain the sterols composition in the fruit of Calyx seu fructus physalis, seed and the calyx, that has reported has: Calyx seu fructus physalis sterol A, Calyx seu fructus physalis sterol B, stigmasterol, 14A-methyl-5A-P (11) alkene cholesterol, 14A-methyl gallbladder steroid-9 alkene-3B alcohol, multiple 4A-methylsterol (being mainly this sterol of standing grain and obtusifoliol), multiple 4 demethylation sterols (as cholesterol, 24-ethyl cholesterol etc.), multiple triterpene-3B monohydric alcohol (as encircling female Fructus Ananadis comosi alkanol, cycloartenol, lanoline-8-alkene-3B one alcohol etc.).(4) lipid: contain eight kinds of fatty acids in the Calyx seu fructus physalis seed, they are respectively: hexadecanoic acid, valeric acid, octadecenoic acid, 12,15-octadecene diacid, sad, 9-octadecenoic acid, octadecane, arachic acid, tetradecanoic acid.(5) pigment: all contain the pigment material in the fruit of Calyx seu fructus physalis, Constellation calyx, leaf and the root.The Calyx seu fructus physalis fruit contains Calyx seu fructus physalis red pigment, phytolaccanine, Quercetin and carotenoid (as zeaxanthin, phylloxanthin, B-kryptoxanthin etc.); Contain cryptoxanthine, A-carotene, B-carotene and carotenoid (carotenoid such as zeaxanthin, phylloxanthin, B-kryptoxanthin etc.) in the Calyx Physalis; The Calyx seu fructus physalis leaf contains B-cryptoxanthine, new B-cryptoxanthine, cetylate, physalein and cis-isomer, B-carotene, flavescence element and auroxanthin; Contain hystonin in the Radix physalis.Other composition has polysaccharide, the tannin of Calyx seu fructus physalis.
The inventor has carried out experimentation to some resistant effects of Calyx seu fructus physalis micro powder capsules, and is specific as follows:
The preparation of Calyx seu fructus physalis micro powder capsules: get Calyx seu fructus physalis, drying, encapsulated after the micronizing, promptly get capsule.
1, antiulcer action
60 of mices, 22-25g, male and female half and half, be divided into matched group at random, the cimetidine group, Calyx seu fructus physalis high dose group (1g/kg), dosage group (0.5g/kg) in the Calyx seu fructus physalis, Calyx seu fructus physalis low dose group (0.25g/kg), totally 5 groups, be administered once by described medicine of table 1 and dosage ig every day, capacity water such as matched group ig, continuous 3d, fasting 24h after the 2d administration, freely drink water, 1h fixes mice after the 3d administration, and head is upwards vertical to be immersed in the 20-22 ℃ of water, and water level is to xiphoid-process portion, put to death animal behind the 20h, cut open and get stomach, the ligation pylorus is annotated normal saline and make its expansion in stomach, putting into 0.5% formaldehyde immersion 5min tailing edge greater gastric curvature cuts off stomach, amplify 10 times of counting ulcer numbers under anatomical lens, experimental result adopts the t check to take statistics to learn and handles, as a result the Calyx seu fructus physalis height, in, low dose group all can obviously suppress the formation of mice water logging stress ulcer, show that Calyx seu fructus physalis has tangible antiulcer action, sees Table 1.
Table 1 Calyx seu fructus physalis is to mice water logging stress ulcer influence (x ± s)
| Group | Example number (n) | Dosage (g/kg) | The ulcer number |
| Matched group | 12 | - | 26.31±9.24 |
| Cimetidine | 12 | 1 | 7.22±2.71 ** |
| Calyx seu fructus physalis | 12 | 1 | 5.01±2.13 ** |
| 12 | 0.5 | 5.57±3.51 ** | |
| 12 | 0.25 | 7.60±4.11 ** |
Annotate: compare * p＜0.05, * * P＜0.01 with matched group.
2, the effect of anti-helicobacter pylori
2.1 bacteriostatic test
The pylorus spiral is inoculated on the helicobacter pylori isolation medium agar plate punching (aperture 5mm on culture medium.) be added in each hole after 1: 10 with sterile purified water dilute acid starch end one-tenth, put anaerobic jar and cultivate observed result after 3 days for interior 37 ℃, measure bacteriostatic diameter.Drug level is 10% o'clock as a result, and inhibition zone is 15mm, sees Table 2.
2.2 minimum inhibitory concentration (MIC) test
Also add respectively in the helicobacter pylori isolation medium agar with sterile purified water dilute acid starch end, mixing makes drug level become 1%, 0.5%, and 0.25%, 0.125%, 0.1%, 0.05%, 0.025%, 0.0125%.Getting helicobacter pylori is inoculated on each drug level culture medium.Putting in the anaerobic jar 37 ℃ and cultivate and observe the helicobacter pylori growing state after 3 days, is the minimum inhibitory concentration of this medicine with the high dilution of the medicine of integral asepsis growth.The minimum inhibitory concentration of Calyx seu fructus physalis (MIC) is 0.125% as a result, sees Table 2.
2.3 minimum bactericidal concentration (MBC) test
Get the agar block at the inoculated bacteria place of asepsis growth in the MIC test, be put on the helicobacter pylori isolation medium agar plate that does not contain reagent.Put 37 ℃ of cultivations in the anaerobic jar, observed result after 3 days is observed bacterial growth situation on the culture medium, is the minimum bactericidal concentration of this medicine with the high dilution of the reagent of integral asepsis growth.The minimum bactericidal concentration of Calyx seu fructus physalis (MBC) is 0.25% as a result, sees Table 2.
The anti-helicobacter pylori experiment shows: Calyx seu fructus physalis has tangible anti-helicobacter pylori activity.
The effect of table 2 Calyx seu fructus physalis anti-helicobacter pylori
Annotate :+: bacteria growing is arranged: asepsis growth.
3, resistive connection enteritis effect
63 of SD rats, body weight 193.1 ± 8.2g, group, all the other animals only are injected in the modeling of colon pipe with 15% acetic acid 0.2ml/, 3 modeling rats dissections of execution in the 5th day in contrast to get 10, colon portion shows as mucous hyperemia, edema, ulcer, shows that rat colonitis forms.At random the modeling animal is divided into dosage group (0.4g/kg) in model group (isometric(al) ordinary water), sulfasalazine group (0.5g/kg), Calyx seu fructus physalis high dose group (0.8g/kg), the Calyx seu fructus physalis, 5 groups of Calyx seu fructus physalis low dose group (0.2g/kg), adds matched group totally 6 groups.Each treated animal is by medicine and dosage are irritated stomach separately, every day 1 time, continuous 20 days, 24 hours femoral artery of fasting are got blood system from serum after the last administration, survey il-1 β (IL-1 β) in the serum with microplate reader in the 492nm place,, cut open and get colon observation colon anatomy index, and mark: 0 minute: harmless by following standard; 1 minute: ulcer did not appear in mucosa hyperemia, edema; 2 minutes: mucosa hyperemia, edema, moderate erosion, no ulcer; 3 minutes: mucosa hyperemia, edema, the moderate erosion has single ulcer; 4 minutes: mucosa hyperemia, edema, the severe erosion has many places ulcer; 5 minutes: mucosa hyperemia, edema, the severe erosion had＞1mm ulcer.The result shows that Calyx seu fructus physalis can obviously alleviate the damage of intestines of colitis rat, reduces colitis rat blood serum IL-1 β level, shows that Calyx seu fructus physalis has the effect of rat colonitis due to the tangible anti-acetic acid.See Table 3, table 4.
Table 3 Calyx seu fructus physalis is to the influence of colitis rat blood serum IL-1 β content (x ± s)
| Group | n | Dosage (g/kg) | IL-1β(pg/ml) |
| Matched group | 10 | - | 8.03±0.70 |
| Model group | 10 | - | 12.33±1.18 |
| Sulfasalazine | 10 | 0.5 | 8.42±0.92** |
| Calyx seu fructus physalis | 10 | 0.8 | 7.85±0.76** |
| 10 | 0.4 | 8.71±0.85** | |
| 10 | 0.2 | 9.64±0.87** |
Annotate: compare * p＜0.05, * * P＜0.01 with model group.
The influence that table 4 Calyx seu fructus physalis is marked to the damage of colitis rat tissue (x ± s)
| Group | n | Dosage (g/kg) | Tissue injury's scoring |
| Matched group | 10 | - | 0 |
| Model group | 10 | - | 4.17±0.75 |
| Sulfasalazine | 10 | 0.5 | 2.30±0.49** |
| Calyx seu fructus physalis | 10 | 0.8 | 2.17±0.40** |
| 10 | 0.4 | 2.79±0.51** | |
| 10 | 0.2 | 3.48±0.61* |
Annotate: compare * p＜0.05, * * P＜0.01 with model group.
4, to the influence of carbon tetrachloride induced mice acute liver damage:
Get 120 of mices, male and female half and half, body weight 19.49 ± 0.98g. is divided into matched group at random, liver injury model group, dosage group (0.5g/kg), Calyx seu fructus physalis low dose group (0.25g/kg), totally six groups in liver-protecting tablet group and Calyx seu fructus physalis high dose group (1g/kg), the Calyx seu fructus physalis.Each administration group is pressed the administration of table l dosage lumbar injection (ip), matched group and model group ip isometric(al) normal saline, and continuous once a day 5d, 1h after the last administration, each administration group and model group animal are pressed 0.1ml/log and irritate stomach (ig) 0.1%CCl
4Vegetable oil solution, matched group is the isometric vegetable oil of ig then, poisoning 24h, and fasting 16h, animal freely drinks water, igCCl
424h plucks eyeball and gets blood behind the vegetable oil solution, conventional separation of serum, respectively get 10 parts of blood serum samples and measure aspartic acid aminotransferase (AST), other gets 10 parts of determination of serum ALTs (ALT), measures with U.S. product MD-100 type semi-automatic biochemical analyzer and carries out, and each group data and model group are relatively, t check between statistical method employing group, every treated animal extracts 10 (male and female half and half) and wins liver, and 10% formalin fixed is carried out histopathologic examination.The pathological grading standard is: one, hepatocellular degeneration: hepatocyte kitchen range shape cloudy swelling in (ten) lobules of liver, and (10) hepatocyte cloudy swelling accounts for lobules of liver 1/3, and (10) hepatocyte cloudy swelling accounts for more than the lobules of liver l/2, and the change of hepatocyte hydropic degeneration balloon sample occurs.Two, hepatic necrosis: see spotty necrosis around (ten) central veins of hepatic lobules, (10) hepatic necrosis is kitchen range shape or lamellar, accounts for lobules of liver 1/3, and (10) hepatic necrosis accounts for lobules of liver 1/2.Three, cell infiltration: (ten) portal area has and is dispersed in cell infiltration on a small quantity, and obvious cell infiltration is seen in (10) portal area, sees all around (10) portal area and the necrotic area hepatocyte that scorching thin the race soak into.The result: Calyx seu fructus physalis can obviously reduce CCl
4Caused AST and ALT raise, and alleviate CCl
4Caused hepatocellular degeneration, hepatic necrosis and cell infiltration show that Calyx seu fructus physalis can be to CCl
4Due to hepatic injury significant protective effect (table 5, table 6 are arranged; Accompanying drawing 1～6).
Table 5 couple CCl
4The influence of acute liver damage mice serum AST, ALT (x ± s)
| Group | Dosage (g/kg) | n | AST(Iu/L) | ALT(Iu/L) |
| Matched group | - | 10 | 116.22±14.36 | 60.13±17.58 |
| Model group | - | 10 | 827.35±341.11 | 473.02±201.40 |
| Liver-protecting tablet | 3 | 10 | 169.71±67.12** | 151.00±65.10** |
| Calyx seu fructus physalis | 1 | 10 | 131.61±18.34** | 69.32±19.00** |
| 0.5 | 10 | 109.17±15.23** | 60.49±18.32** | |
| 0.25 | 10 | 180.55±67.81** | 127.69±58.32** |
Annotate: compare * p＜0.05, * * P＜0.01 with model group.
The comparison that table 6 pair CCl4 acute liver damage mice histopathology changes
Annotate: compare * p＜0.05, * * P＜0.01 with model group.
5, choleretic effect
60 of male rats, body weight 265.33 ± 8.39g, be divided into matched group at random, Yinzhihuang Injection group (being called for short " mattress Cape jasmine Huang " in the table), Calyx seu fructus physalis high dose group (0.8g/kg), dosage group (0.4g/kg) in the Calyx seu fructus physalis, Calyx seu fructus physalis low dose group (0.2g/kg), totally 5 groups, water is can't help in the 12h fasting before the experiment, anaesthetize with pentobarbital sodium 50mg/kg ip during experiment, it is fixing to face upward the position, open the abdominal cavity, ligation bile duct pars papillaris, make " V " shape otch to the liver direction, insert the plastic cannula of external diameter 1mm, ligation fixed plastics pipe is in bile duct, close the abdominal cavity, cover otch with the normal saline gauze, collect bile 30min after waiting to stablize 20min, respectively organize rat then by table 5 medicine and dosage ip administration, capacity normal saline such as matched group ip are collected bile after the administration, every 30min metering once, be total to 2h, the result shows that Calyx seu fructus physalis can obviously increase biliary secretion, shows that Calyx seu fructus physalis has tangible choleretic effect.See Table 7.
Table 7 Calyx seu fructus physalis is to the influence of big cowardly hidropoiesis (x ± s)
Annotate: compare * p＜0.05, * * P＜0.01 with matched group.|
6, antiinflammatory action
50 of mices, ♀, ♂ half and half, body weight: 20.21 ± 1.15g, be divided into matched group at random, the prednisone group, Calyx seu fructus physalis high dose group (1g/kg), dosage group (0.5g/kg) in the Calyx seu fructus physalis, Calyx seu fructus physalis low dose group (0.25g/kg), totally 5 groups, each treated animal is all by medicine and dosage ig administration separately, once a day, continuous 3d, the every Mus auris dextra of 30min melted paraxylene 0.03ml causes inflammation after the last administration, causes scorching back 30min execution animal and cuts ears, sweep away round auricle with internal diameter 8mm card punch at the same position of left and right sides ear, weighing with analytical balance, is the swelling degree with the difference of left and right sides auricle weight, and each organizes swelling degree and relatively t check between the work group of matched group.The result shows that Calyx seu fructus physalis can obviously reduce the mice auricle swelling degree due to the dimethylbenzene, shows that Calyx seu fructus physalis has tangible antiinflammatory action is arranged, and the results are shown in Table 8.
The inhibitory action of table 8 Calyx seu fructus physalis xylol induced mice auricle edema (x ± s)
| Group | Dosage (g/kg) | n | The swelling degree | Suppression ratio (%) |
| Contrast | - | 10 | 5.44±0.58 | - |
| The prednisone group | 0.025 | 10 | 1.61±0.32 ** | 70.4 |
| Calyx seu fructus physalis | 1 | 10 | 3.52±0.50 ** | 35.3 |
| 0.5 | 10 | 4.26±0.34 ** | 21.7 | |
| 0.25 | 10 | 4.81±0.42 * | 11.6 |
Annotate: compare * p＜0.05, * * P＜0.01 with matched group.
7, analgesic activity (torsional technique)
50 of mices, ♀, ♂ half and half, body weight 20.24 ± 1.19g, dosage group (0.5g/kg), Calyx seu fructus physalis low dose group (0.25g/kg), totally 5 groups in matched group, morphine group, Calyx seu fructus physalis high dose group (1g/kg), the Calyx seu fructus physalis, each treated animal is complied with medicine and dosage ig separately, once a day, continuous 3d, last cause pain for the every Mus iP 0.6% glacial acetic acid 0.2ml of back 1h, record causes the number of animals and each Mus that produce writhing response in the 15min of pain back and turns round the body number of times, and each administration group and matched group are relatively.The result shows that Calyx seu fructus physalis can obviously suppress the mouse writhing number of times due to the acetic acid, shows that Calyx seu fructus physalis has significant analgesia role.See Table 9.
Table 9 Calyx seu fructus physalis Dichlorodiphenyl Acetate causes the influence (x ± s) of mouse writhing
| Group | Dosage (g/kg) | n | Turn round the body number of times (inferior/15min) | Suppression ratio (%) |
| Contrast | - | 10 | 48.11±8.21 | - |
| Morphine | 0.02 | 10 | 0.00±0.00 | 100.00 |
| Calyx seu fructus physalis | 1 | 10 | 21.50±7.01 ** | 55.3 |
| 0.5 | 10 | 24.09±7.48 ** | 50.00 | |
| 0.25 | 10 | 32.67±11.09 ** | 32.1 |
Annotate: compare * p＜0.05, * * P＜0.01 with matched group.
Conclusion: experimental result shows: Calyx seu fructus physalis has tangible antiulcer action, anti-helicobacter pylori, resistive connection enteritis, protects the liver, function of gallbladder promoting, antiinflammatory and analgesic activity.
Model case: yellow born, the man, identity card 52011119441023XXXX suffers from surplus gastric ulcer, the erosive gastritis ten year, has esophagitis concurrently, suffers from gout simultaneously.The patient often shows as and has a stomach-ache, inappetence, vomiting, arthralgia.Take Calyx seu fructus physalis crude drug powder, one day twice, each 3g, medication symptom on the same day obviously alleviates, and inferior symptom is in the future eliminated, logotype ten days, recovery from illness.So far do not see recurrence in 4 years.Now not only can eat Fructus Capsici, drink, even take, not see that also stomach has significant discomfort the great colchicine of stomach irritation (for the treatment gout).
Compared with prior art, the present invention has overcome and has only got the defective that Calyx Physalis seed is used as medicine in the prior art, the application of Calyx seu fructus physalis in the medicine of preparation treatment digestive system disease is provided, be to be the preparation of crude drug with the Calyx seu fructus physalis, pharmacological action is clear and definite, quality is more easy to control, and process for preparing medicine provided by the present invention is simple, cost is low, evident in efficacy, untoward reaction is low, can effectively treat various digestive system disease, especially to gastric ulcer, gastritis, gastric cancer, gastroptosis, esophagitis, cholecystitis, the esophageal carcinoma, hepatitis, pancreatitis, diabetes, liver cirrhosis, treatment of diseases such as duodenal ulcer have specially good effect with the aspect that is good for the stomach, and more the back is difficult for recurrence.
The present invention is with all herbal medicine, and its curative effect is good with the curative effect of root, stem, leaf, and seed can be used for the plantation of medical material, can effectively protect the medicine source.
The therapeutic domain of present patent application is wide, and curative effect is obvious, and especially curative effect is distinguished in the treatment of digestive tract ulcer, and its therapeutic effect is identical with classical medicine " omeprazole ".
Description of drawings
Fig. 1 matched group liver organization mechanism is normal;
Fig. 2 model group hepatocyte focal necrosis;
Fig. 3 liver-protecting tablet group slight hepatic cell hydropic degeneration;
Fig. 4 Calyx seu fructus physalis high dose group slight hepatic cell hydropic degeneration;
Dosage group slight hepatic cell hydropic degeneration in Fig. 5 Calyx seu fructus physalis;
Fig. 6 Calyx seu fructus physalis low dose group slight hepatic cell hydropic degeneration.
The specific embodiment
Embodiment 1: get the Calyx seu fructus physalis herb, drying is put into super micron mill and pulverized, and is encapsulated, and every 0.3～0.5g promptly gets capsule.Oral, one day twice, each 1～6.
Embodiment 2: get the Calyx seu fructus physalis leaf, drying is pulverized, and adds 10 times of water gagings and decocts 3 times at 98 ℃, filter, and merging filtrate, it is 1.28 extractum that filtrate decompression is concentrated into 80 ℃ of relative densities, drying is pulverized, and adds pharmaceutic adjuvant, mixing, tabletting promptly gets tablet.
Embodiment 3: get root, stem and the leaf of Calyx seu fructus physalis, drying is pulverized, and adds 3 times of amount alcohol heating reflux and extracts 3 times, filter, and merging filtrate, it is 1.30 extractum that filtrate decompression is concentrated into 80 ℃ of relative densities, and drying is pulverized, and adds adjuvant and granulates, and pack promptly gets granule.
Embodiment 4: get Radix physalis, drying is pulverized, and adds 20 times of water gaging microwave extractioies 2 times, filter, and merging filtrate, filtrate microwave vacuum drying to 80 ℃ relative density is 1.50 extractum, drying is pulverized, and adds pharmaceutic adjuvant, mixing, tabletting promptly gets capsule.
Embodiment 5: get the stem and the leaf of Calyx seu fructus physalis, and drying, micronizing adds 8 times of amount ethanol percolate extraction, filters, and filtrate microwave vacuum drying to 80 ℃ relative density is 1.36 extractum, and drying is pulverized, and granulates, and is encapsulated, promptly gets capsule.
Claims (10)
1. the application of Calyx seu fructus physalis in the medicine of preparation treatment digestive system disease.
2. the application of Calyx seu fructus physalis in the medicine of preparation treatment digestive tract ulcer.
3. the application of Calyx seu fructus physalis in preparation treatment dyspepsia, shortage gastric motility, gastritis, gastroptosis, gastric cancer, esophagitis, cholecystitis, pancreatitic medicine.
4. the application of Calyx seu fructus physalis in the medicine of preparation treatment rectal cancer, colon cancer.
5. the application of Calyx seu fructus physalis in the medicine of preparation treatment hepatitis, liver cirrhosis, hepatocarcinoma.
6. medicine for the treatment of digestive system disease, it is characterized in that: it is to be that crude drug is prepared from the Calyx seu fructus physalis, and described Calyx seu fructus physalis comprises Radix physalis, Calyx seu fructus physalis stem, Calyx seu fructus physalis leaf, Calyx seu fructus physalis fruit, Calyx Physalis, Calyx seu fructus physalis seed.
7. the preparation method of the medicine of the described treatment digestive system disease of claim 6, it is characterized in that: with the Calyx seu fructus physalis micronizing, preparation process is made various dosage forms routinely.
8. the preparation method of the medicine of the described treatment digestive system disease of claim 6 is characterized in that: get Calyx seu fructus physalis and add water or ethanol extraction, filter, filtrate is condensed into extractum, and preparation process is made various dosage forms routinely.
9. according to the preparation method of the medicine of the described treatment digestive system disease of claim 8, it is characterized in that: get Calyx seu fructus physalis and pulverize, add 3～20 times of water gagings or ethanol extraction 1～3 time, filter, merging filtrate, it is 1.00～1.50 extractum that filtrate is concentrated into 80 ℃ of relative densities, and preparation process is made various dosage forms routinely.
10. according to the preparation method of the medicine of the described treatment digestive system disease of claim 9, it is characterized in that: the method for described water or ethanol extraction comprises that decoction, microwave extraction and percolation extract; The method for concentration of described filtrate comprises that vacuum decompression concentrates and microwave vacuum drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810300310XA CN101244153B (en) | 2008-02-01 | 2008-02-01 | Application of alkekengi in preparing medicament for treating digestive system disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810300310XA CN101244153B (en) | 2008-02-01 | 2008-02-01 | Application of alkekengi in preparing medicament for treating digestive system disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101244153A true CN101244153A (en) | 2008-08-20 |
| CN101244153B CN101244153B (en) | 2012-05-09 |
Family
ID=39944974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810300310XA Expired - Fee Related CN101244153B (en) | 2008-02-01 | 2008-02-01 | Application of alkekengi in preparing medicament for treating digestive system disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101244153B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872261A (en) * | 2012-09-26 | 2013-01-16 | 济南星懿医药技术有限公司 | Application of straw berry tomato in preparing medicine for treating acute cholecystitis |
| CN102971000A (en) * | 2010-05-28 | 2013-03-13 | 金亨一 | A composition comprising the extract of Physalis alkekengi var francheti Hort as an active ingredient for preventing and treating inflammatory diseases |
| CN103191323A (en) * | 2013-04-12 | 2013-07-10 | 张忠民 | Medicine for treating ascites due to cirrhosis |
| CN103230013A (en) * | 2013-05-11 | 2013-08-07 | 哈尔滨工业大学 | Preparation method of alkekengi powder |
| CN103933209A (en) * | 2014-04-03 | 2014-07-23 | 沈阳化工大学 | Method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx |
| CN104857063A (en) * | 2015-06-17 | 2015-08-26 | 产俊涛 | Traditional Chinese medicine composition for treating liver cancer and application thereof |
| CN105949272A (en) * | 2016-05-20 | 2016-09-21 | 天津中医药大学 | With a-physalin Y, method for extracting same and application of with a-physalin Y |
| CN106480207A (en) * | 2016-11-16 | 2017-03-08 | 杭州师范大学 | A kind of nucleotide sequence for differentiating wintercherry, specificity labeled primers and method |
| CN107582855A (en) * | 2017-09-19 | 2018-01-16 | 陈宏� | A kind of Chinese medicine composition for treating Childhood Peptic Ulcer and stomach suspension piece |
| CN108392484A (en) * | 2018-02-06 | 2018-08-14 | 贵州省食品药品检验所 | Steroidal compounds are preparing the application in preventing or treating the drug of gastric ulcer and its complication |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846736A (en) * | 2005-04-04 | 2006-10-18 | 申景太 | Intestine recovering groundcherry capsule and its prepn process |
-
2008
- 2008-02-01 CN CN200810300310XA patent/CN101244153B/en not_active Expired - Fee Related
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102971000A (en) * | 2010-05-28 | 2013-03-13 | 金亨一 | A composition comprising the extract of Physalis alkekengi var francheti Hort as an active ingredient for preventing and treating inflammatory diseases |
| EP2575842A2 (en) * | 2010-05-28 | 2013-04-10 | Kim, Hyung Il | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases |
| EP2575842A4 (en) * | 2010-05-28 | 2013-10-30 | Kim Hyung Il | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases |
| CN102872261B (en) * | 2012-09-26 | 2016-03-16 | 李秉寿 | The application of Physalis pubescens L. in the medicine of preparation treatment acute cholecystitis |
| CN102872261A (en) * | 2012-09-26 | 2013-01-16 | 济南星懿医药技术有限公司 | Application of straw berry tomato in preparing medicine for treating acute cholecystitis |
| CN103191323A (en) * | 2013-04-12 | 2013-07-10 | 张忠民 | Medicine for treating ascites due to cirrhosis |
| CN103230013A (en) * | 2013-05-11 | 2013-08-07 | 哈尔滨工业大学 | Preparation method of alkekengi powder |
| CN103933209A (en) * | 2014-04-03 | 2014-07-23 | 沈阳化工大学 | Method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx |
| CN104857063A (en) * | 2015-06-17 | 2015-08-26 | 产俊涛 | Traditional Chinese medicine composition for treating liver cancer and application thereof |
| CN105949272A (en) * | 2016-05-20 | 2016-09-21 | 天津中医药大学 | With a-physalin Y, method for extracting same and application of with a-physalin Y |
| CN105949272B (en) * | 2016-05-20 | 2017-08-29 | 天津中医药大学 | Wityaphysalin Y and extracting method and purposes |
| CN106480207A (en) * | 2016-11-16 | 2017-03-08 | 杭州师范大学 | A kind of nucleotide sequence for differentiating wintercherry, specificity labeled primers and method |
| CN106480207B (en) * | 2016-11-16 | 2019-09-20 | 杭州师范大学 | A kind of nucleotide sequence, specificity labeled primers and method identifying wintercherry |
| CN107582855A (en) * | 2017-09-19 | 2018-01-16 | 陈宏� | A kind of Chinese medicine composition for treating Childhood Peptic Ulcer and stomach suspension piece |
| CN107582855B (en) * | 2017-09-19 | 2021-07-06 | 陈宏� | Traditional Chinese medicine composition for treating children peptic ulcer and gastric suspension tablet |
| CN108392484A (en) * | 2018-02-06 | 2018-08-14 | 贵州省食品药品检验所 | Steroidal compounds are preparing the application in preventing or treating the drug of gastric ulcer and its complication |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101244153B (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101244153B (en) | Application of alkekengi in preparing medicament for treating digestive system disease | |
| Gadekar et al. | A potential of some medicinal plants as an antiulcer agents | |
| Khare | Ayurvedic pharmacopoeial plant drugs: expanded therapeutics | |
| CN101554462A (en) | Medicament for curing cancer | |
| CN110035763A (en) | For treating the composition and its method of parasitic disease | |
| Islam et al. | A review on medicinal uses of different plants of Euphorbiaceae family | |
| CN102836228A (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| Idu et al. | Ethnobotanical uses of plants among the binis in the treatment of ophthalmic and ENT (ear, nose and throat) ailments | |
| Choudhary et al. | Vaibidang (embelia ribes): A potential herbal drug in ayurveda with anthelmintic property | |
| CN110393715A (en) | The application of drug occurs as preparation treatment atrophic gastritis and/or blocking gastritis cancer conversion for Nuciferine and Lotus Leafextract | |
| CN101961366B (en) | Preparation method of malan straw extract, malan straw product, pharmaceutical composition and application thereof | |
| CN107319332A (en) | A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof | |
| KR0160108B1 (en) | Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| Omale et al. | Anti-Ulcer Properties Of Alkaloids Isolated From The Fruit Pulp Of Cucumis Metuliferous (Curcurbitaceae) | |
| CN101199652B (en) | Medicament for treating acute, subacute eczema and preparing method thereof | |
| CN1939499B (en) | Jixiangcao extract, its preparation, medicinal composition and uses | |
| Chaudhary et al. | Concise review on Asparagus racemosus and its role as nutraceuticals and functional foods | |
| CN101632777A (en) | Chinese medicinal composition for clearing away heat and toxic material, dispersing food and freeing bowels and preparation method thereof | |
| KR102493496B1 (en) | Composition for alleviating and improving liver damage derived from natural products | |
| Mane et al. | Uraria Picta (Jacq.): a review on ethnomedical uses, phytochemistry, and biological activities | |
| KR102515763B1 (en) | Korean Medicinal Compounds for Improving Gastroesophageal Reflux Disease Comprising Herbal Mixture | |
| Mandal et al. | Pharmacological potentialities of Trichosanthes dioica roxb.(Cucurbitaceae): an overview | |
| CN105663208A (en) | Drug combination for preventing and treating cirrhotic ascites and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 Termination date: 20210201 |